Insider Transactions in Q2 2024 at Madrigal Pharmaceuticals, Inc. (MDGL)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 25
2024
|
Kenneth Bate |
BUY
Grant, award, or other acquisition
|
Direct |
714
+27.19%
|
-
|
|
Jun 25
2024
|
Fred B Craves Director |
BUY
Grant, award, or other acquisition
|
Direct |
714
+0.19%
|
-
|
|
Jun 25
2024
|
Paul A Friedman |
BUY
Grant, award, or other acquisition
|
Direct |
714
+0.38%
|
-
|
|
Jun 25
2024
|
Richard S Levy |
BUY
Grant, award, or other acquisition
|
Direct |
714
+6.09%
|
-
|
|
Jun 25
2024
|
James M Daly |
BUY
Grant, award, or other acquisition
|
Direct |
714
+27.19%
|
-
|
|
Jun 25
2024
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
2,856
+0.42%
|
-
|
|
Jun 14
2024
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
1,900
-25.68%
|
$532,000
$280.0 P/Share
|
|
Jun 14
2024
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
1,900
+20.43%
|
$165,300
$87.09 P/Share
|
|
Jun 12
2024
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
2,000
-26.67%
|
$570,000
$285.0 P/Share
|
|
Jun 12
2024
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+21.05%
|
$174,000
$87.92 P/Share
|
|
Jun 11
2024
|
Fred B Craves Director |
SELL
Bona fide gift
|
Indirect |
45,852
-80.35%
|
-
|
|
Jun 11
2024
|
Fred B Craves Director |
SELL
Bona fide gift
|
Direct |
39,000
-9.43%
|
-
|
|
May 21
2024
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
1,036
-15.85%
|
$239,316
$231.34 P/Share
|
|
May 14
2024
|
Fred B Craves Director |
SELL
Open market or private sale
|
Direct |
22,489
-0.53%
|
$4,835,135
$215.4 P/Share
|
|
May 14
2024
|
Fred B Craves Director |
BUY
Exercise of conversion of derivative security
|
Direct |
22,489
+2.55%
|
$2,293,878
$102.76 P/Share
|
|
Apr 08
2024
|
Paul A Friedman |
SELL
Open market or private sale
|
Direct |
26,270
-1.87%
|
$6,436,150
$245.85 P/Share
|
|
Apr 08
2024
|
Paul A Friedman |
BUY
Exercise of conversion of derivative security
|
Direct |
26,270
+11.03%
|
$236,430
$9.45 P/Share
|
|
Apr 08
2024
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
2,676
-0.1%
|
$658,296
$246.17 P/Share
|
|
Apr 08
2024
|
Rebecca Taub Pres., R&D, and CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,676
+0.58%
|
$24,084
$9.45 P/Share
|
|
Apr 05
2024
|
Paul A Friedman |
SELL
Open market or private sale
|
Direct |
27,613
-1.95%
|
$6,709,959
$243.19 P/Share
|
|
Apr 05
2024
|
Paul A Friedman |
BUY
Exercise of conversion of derivative security
|
Direct |
27,613
+11.46%
|
$248,517
$9.45 P/Share
|
|
Apr 05
2024
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
27,506
-0.96%
|
$6,656,452
$242.86 P/Share
|
|
Apr 05
2024
|
Rebecca Taub Pres., R&D, and CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,506
+5.35%
|
$247,554
$9.45 P/Share
|
|
Apr 04
2024
|
Paul A Friedman |
SELL
Open market or private sale
|
Direct |
18,710
-1.19%
|
$4,565,240
$244.68 P/Share
|
|
Apr 04
2024
|
Paul A Friedman |
BUY
Exercise of conversion of derivative security
|
Direct |
18,710
+8.38%
|
$168,390
$9.45 P/Share
|
|
Apr 04
2024
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
18,537
-0.49%
|
$4,523,028
$244.5 P/Share
|
|
Apr 04
2024
|
Rebecca Taub Pres., R&D, and CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,537
+3.74%
|
$166,833
$9.45 P/Share
|
|
Apr 03
2024
|
Paul A Friedman |
SELL
Open market or private sale
|
Direct |
27,407
-2.66%
|
$6,687,308
$244.37 P/Share
|
|
Apr 03
2024
|
Paul A Friedman |
BUY
Exercise of conversion of derivative security
|
Direct |
27,407
+11.39%
|
$246,663
$9.45 P/Share
|
|
Apr 03
2024
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
27,845
-1.16%
|
$6,794,180
$244.4 P/Share
|
|
Apr 03
2024
|
Rebecca Taub Pres., R&D, and CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,845
+5.41%
|
$250,605
$9.45 P/Share
|
|
Apr 02
2024
|
James M Daly |
SELL
Open market or private sale
|
Direct |
10,912
-27.97%
|
$2,673,440
$245.69 P/Share
|
|
Apr 02
2024
|
James M Daly |
BUY
Exercise of conversion of derivative security
|
Direct |
10,912
+47.4%
|
$1,145,760
$105.08 P/Share
|
|
Apr 02
2024
|
Kenneth Bate |
SELL
Open market or private sale
|
Direct |
11,212
-24.5%
|
$2,758,152
$246.16 P/Share
|
|
Apr 02
2024
|
Kenneth Bate |
BUY
Exercise of conversion of derivative security
|
Direct |
11,212
+47.46%
|
$1,177,260
$105.08 P/Share
|
|
Apr 01
2024
|
Richard S Levy |
SELL
Open market or private sale
|
Direct |
11,000
-10.99%
|
$2,860,000
$260.36 P/Share
|
|
Apr 01
2024
|
Richard S Levy |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+23.31%
|
$649,000
$59.21 P/Share
|
|
Apr 01
2024
|
James M Daly |
SELL
Open market or private sale
|
Direct |
21,577
-24.39%
|
$5,610,020
$260.94 P/Share
|
|
Apr 01
2024
|
James M Daly |
BUY
Exercise of conversion of derivative security
|
Direct |
21,577
+27.51%
|
$2,200,854
$102.76 P/Share
|
|
Apr 01
2024
|
Kenneth Bate |
SELL
Open market or private sale
|
Direct |
21,277
-24.11%
|
$5,532,020
$260.91 P/Share
|
|
Apr 01
2024
|
Kenneth Bate |
BUY
Exercise of conversion of derivative security
|
Direct |
21,277
+28.2%
|
$1,510,667
$71.66 P/Share
|